- Platform
- Roche Ventana Benchmark Ultra
- Clone/manufacturer
- P504S (AMACR) + 34BE12 + p63 (790-4536 - Roche Ventana / 790-6011 for P504S)
- Antibody dilution
- Predilute
- Antibody incubation time/temp
- 20 mins at ambient room temperature
- Antigen retrieval buffer time/temp
- Ventana CC1 48 mins at 100°C
- Amplification
- Not applicable
- Detection kit
- 760-500 Ventana UltraView
- Program (mark)
- General 2025 (5/5)
PIN‑4 is a triple IHC antibody cocktail composed of p63, a high molecular‑weight cytokeratin (34βE12) and AMACR/P504S, designed to aid in distinguishing prostatic adenocarcinoma from benign lesions. Malignant glands lack basal cells (therefore show loss of p63 and HMWCK staining) while often demonstrating increased cytoplasmic AMACR expression, whereas benign glands retain basal cell markers and typically lack AMACR staining. This combined staining pattern makes PIN‑4 particularly useful in evaluating small foci of atypical glands and in resolving challenging prostate needle biopsy interpretations (1).
Recommended Controls
The criteria for acceptable staining is nuclear (p63), cytoplasmic (high molecular weight cytokeratin) and granular cytoplasmic (AMACR/P504S). The recommended negative controls to use include testes, tonsil or appendix. For the positive control, normal prostate including prostate cancer should show positive staining in the normal prostatic epithelium as well as in the tumour cells.
Expected staining pattern

Prostate cancer including normal prostate (1)

Prostate cancer including normal prostate (2)
Disclaimer
These methods are intended as a guide only. Laboratories that wish to implement these methods should perform internal validation/verification prior to use. The RCPAQAP does not make any claim or warranty for the accuracy or performance of these methods.
References
Ahmed S, Ma B, Xiao GQ. IHC overview. PathologyOutlines.com website. https://www.pathologyoutlines.com/topic/prostateihc.html.
Images of prostate cancer including normal prostate_QAP survey result